Grindeks JSC is opening new representative office in Uzbekistan

Grindeks JSCGrindeks JSC is expanding its activities in the former soviet republics members of Commonwealth of Independent States by opening new representative office in Uzbekistan. The new representative office will have been cooperating with medicines administrating state authorities, Uzbekistan's companies engaged in pharmaceutical and medicinal products wholesale and retail business, as well as providing drug registration processes and medicaments marketing.

Jānis Romanovskis, Chairman of the Management Board of Grindeks JSC, points out: "Former soviet republics members of CIS are, strategically, the most important markets for final dosage forms of medicines manufactured by Grindeks, where the demand for our products, especially for Mildronate®, is increasing every year. Uzbekistan is a perspective developing market, and our new representative office will facilitate to make the most of its resources."

In 2007, export volume to Uzbekistan exceeded half a million LVL. Currently, 10 of our products are registered in Uzbekistan.

The Head of Representative Office is Mastura Kutmatova, and there are totally three employees in the Representative Office.

About JSC Grindeks
JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of Grindeks's products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 92% of the total turnover. The main markets are: the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of "Riga Stock Exchange".

For further information, please visit www.grindeks.lv.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...